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Purpose: Penetrating keratoplasty can restore vision in corneal blindness. However, immunologic rejection threatens graft
survival. Matching donors at swine leukocyte antigen (SLA)-class II convey allo-specific tolerance in a large animal
kidney-transplantation model despite mismatches at SLA-class I. The same matching pattern seems to account for the
blood transfusion effect in kidney transplantation. Relying on the molecular basis of HLAMatchmaker eplets, we assessed
whether this finding would also apply to keratoplasty, and if it would enhance the benefit from matching human leukocyte
antigen (HLA)-class I alone.
Methods: We retrospectively selected two independent cohorts comprising 586 and 975 penetrating keratoplasties. Our
computations revealed a quantitative tolerogenicity factor analogous to the animal model. The number of mismatched
HLA-class I eplets functioned as a factor for conventional histocompatibility. In the first cohort, we empirically determined
the thresholds with the highest predictive power on graft rejection for both factors, and confirmed those thresholds in the
second cohort. We applied Cox proportional hazards regression for these analyses.
Results: The thresholds with highest predictive power revealed 220 eplets2 for the tolerance factor and 10 eplets for HLA-
class I histocompatibility. The respective hazards ratios were 2.22 (p=0.04) versus 3.63 (p<0.01) in the first cohort and
2.09 (p<0.01) versus 1.51 (p=0.02) in the second, confirmatory cohort. The threshold factors proved to be additive in
predicting immune reactions in both cohorts, (hazard ratios 2.66 in cohort 1 versus 1.70; p<0.01 in cohort 2).
Conclusions: Operational tolerance may be inducible by balanced matching of HLA-class I and II HLAMatchmaker
eplets. Furthermore, such tolerance is additive to histocompatibliity at HLA-class I.
Corneal diseases are among the five most common causes
of blindness. Penetrating keratoplasty can restore vision in
most  cases.  Yet  a  substantial  percentage  of  grafts  fail
following immunologic rejection. Cumulative graft survival
after five years is as low as 70% for all keratoplasty indications
despite the widespread use of topical steroids [1].
Systemic immunoprophylaxis can improve overall graft
survival  in  keratoplasty  [2,3].  However,  most
ophthalmologists  are  reluctant  to  prescribe  long-term
systemic immunosuppressants because of potentially serious
side effects.
This  circumstance  reinforces  our  need  for  effective
primary prophylaxis of immunologic graft reactions. Graft
rejection can be prevented employing graft-masquerade by
human leukocyte antigen (HLA) matching, according to a
recent report [4]. The controversial older literature in this field
is  usually  biased  due  to  low  statistical  power  (too  small
cohorts) as well as the probably low accuracy of the HLA
typings at that time [5]. HLA matching is, however, associated
with prolonged waiting times depending on the individual
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HLA  phenotype  [6].  HLA  matching  is  thus  only  routine
nowadays in highly specialized transplantation centers.
Allo-specific  tolerance  is  a  related  but  distinct
mechanism of long-term graft survival after withdrawal of all
immunosuppressants.  Graft  rejection  is  prevented  by
alloantigen-specific  immune  regulation  [7].  Consequently,
donor-specific suppression of delayed-type hypersensitivity
has been demonstrated in some long-term graft acceptors after
kidney  transplantation  [8].  At  least  one  major
histocompatibility  complex  (MHC)  locus  must  match
between donor and recipient to induce allo-specific tolerance
in the miniature swine model of kidney transplantation [9].
Good  histocompatibility  at  the  swine  leukocyte  antigen
(SLA)-class II loci were considered inducive to tolerance in
this large animal model, even when class I loci were loosely
matched [10]. These findings resemble clinical observations
in  long-time  survivors  after  kidney  transplantation  [8,11].
Additionally, the beneficial pre-blood transfusion effect is
also  ascribed  to  a  loosely-matched  HLA-class  I  loci  in
conjunction with closer agreement at HLA-class II [12].
On that basis, we hypothesized that matching at the HLA-
DR locus more closely than at loci HLA-A and -B would
induce graft tolerance in keratoplasty. However, conventional
HLA-allele-based  matching  might  be  inappropriate  for
detecting this effect in the rather small HLA-typed cohorts
available after keratoplasty. Moreover, the standard matching
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between  HLA  alleles.  HLAMatchmaker,  by  contrast,
quantitatively assesses donor-recipient histocompatibility on
the basis of polymorphic amino acid configurations (eplets)
that  represent  structurally  defined  elements  of  the  HLA
epitopes [13]. HLAMatchmaker has already proved effective
for quantitatively assessing HLA-class I histocompatibility in
penetrating keratoplasty [14], and has recently been expanded
to accommodate HLA-class II [15]. This new version enables
us to test for the first time whether tolerance is induced from
balanced  histocompatibility  at  HLA-DR  (class  II)  versus
HLA-A and -B (class I).
METHODS
Patients: We selected two independent cohorts of penetrating
keratoplasties (Table 1). Complete HLA-A, -B, and -DR types
were available for all donors and recipients in both groups.
The first cohort of 586 patients was selected from the
keratoplasty  patients  of  the  University  Eye  Hospital
Düsseldorf,  Germany.  We  included  only  keratoplasties
without specific risk factors from the consecutive series of all
corneal transplantations performed between 1995 and 2004.
Indications were keratoconus, Fuchs endothelial dystrophy,
bullous  keratopathy  and  avascular  corneal  scars.  Repeat
keratoplasties  were  excluded.  We  selected  this  quite
homogeneous subgroup to reduce confounders as much as
possible. HLA types of donors and recipients at loci HLA-A,
-B, and -DR were determined in a single laboratory accredited
by  the  American  Society  for  Histocompatibility  and
Immunogenetics [16]. Class I loci were typed serologically at
low resolution; class II at high resolution using molecular
methods.
The  second  cohort  comprised  975  consecutive
penetrating keratoplasties done at the University Eye Hospital
Freiburg, Germany between 2003 and 2008. Complete HLA
types of donors and recipients at loci HLA-A, -B, and -DR
was the only inclusion criterion. This group thus included low-
risk  and  high-risk  patients  (i.e.,  repeat  keratoplasties,
vascularized corneas and surface disorders). All HLA-types
were determined in a single laboratory. Class I loci were typed
at low, class II at high resolution, all using molecular methods.
Penetrating keratoplasty and medical aftercare: All grafts
were kept in organ culture for at least 6 days. We usually
trephined with the Guided Trephine System (GTS; Polytech
Ophthalmologie  GmbH,  Roßdorf,  Germany)  or  modified
Francescetti's  trephines.  One  milligram  fluocortolone  per
kilogram body mass was initially prescibed and tapered off
within two weeks. Topical gentamycin 0.5% ointment was
applied  at  least  five  times  daily  until  complete  re-
epithelialization. Prednisolone-21-acetate 1% eye drops were
administered five times daily during the first month, four
times daily during the second, three times in the third month,
twice in the fourth, and once in the fifth postoperative month.
Most of the high-risk patients (second cohort only) were also
given systemic cyclosporin and/or mycophenolate mofetil the
for first year following keratoplasty [2].
Assessment of immune reactions: The presence of endothelial
precipitates,  stromal  edema  or  stromal  infiltrates,  and
epithelial rejection lines were diagnosed as immune reactions.
Routine visits were scheduled after 6 weeks and 4 and 12
months. Long-term follow-up took place annually.
Statistical analyses:
HLAMatchmaker  assignments—We  substituted  the
low  resolution  alleles  with  the  high  resolution  alleles
according to allele frequencies as described elsewhere [14].
We  assigned  HLAMatchmaker  eplets  to  the  HLA  alleles
based on HLAMatchmaker version 1.3. We considered only
loci HLA-A, -B and -DR. Mismatched eplets (donor eplets
absent in the recipient) were added up separately for HLA-
classes I and II.
Computation  of  tolerance  and  histocompatibility
factors—We created a function to quantify the tolerogenic
situation  from  the  mismatched  HLAMatchmaker  eplets
according  to  our  aforementioned  hypothesis  (equation,
below). Low or negative values should predict the tolerogenic
situation. This equation reveals that a well matched HLA-
class II may be tolerogenic despite mismatches at HLA-class
TABLE 1. TWO EXAMPLES FOR CALCULATING THE TOLEROGENICITY FACTOR FROM THE DONOR‘S AND RECIPIENT‘S HLA-PHENOTYPES.
Examples HLA class Donor Recipient Eplet
mismatches
Tolerance
factor
Example 1 (tolerogenic situation)
 
HLA-A/B A*0301 A*2402
B*3501
A*0301 A*2402
B*4402 B*5601
4 72–42=33
 
HLA-DR DRB1*1101
DRB1*1501
DRB1*1101
DRB1*0401
7
Example 2 (immunogenic situation)
 
HLA-A/B A*0201 A*0301
B*4402
A*0201 A*2902
B*0702 B*4402
4 212–42=425
 
HLA-DR DRB1*0401
DRB1*1201
DRB1*0101
DRB1*1101
21
        Mismatched donor alleles are in boldface. The count of eplet mismatches was determined by HLAMachmaker. Eplet mismatches
        for HLA-A/B function as factor for conventional histocompatibility. The tolerance factor is calculated from the amount of
        mismatches from HLA-A/B and HLA-DR according to the equation shown in the Methods.
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mismatched constellations in particular.
ftolerogenic(MI, MII) = (MII)2 −  (MI)2
MI symbolizes the number of mismatched HLAMatchmaker
eplets at HLA-class I and MII the corresponding mismatches
at HLA-class II.
We  also  added  up  the  mismatched  HLA-class  I  eplets
separately. Two examples for these calculations are illustrated
in Table 2. Histocompatibility at HLA-class I is a recognized
risk factor for graft rejections after penetrating keratoplasty
[14]. Our aim was to investigate the tolerogenic factor and
HLA-class  I  histocompatibility  factor  as  independent  co-
variates in the same Cox proportional hazards model. We
counted  only  the  immune  reactions  (reversible  and
irreversible) as endpoints. The factors' distributions in the
cohorts are summarized in Table 3.
Threshold estimates and model validation: We assume that
the effect of tolerogenicity and histocompatibility on immune
reactions is nonlinear. We hypothesize that each factor must
have a distinct threshold capable of identifying the beneficial
constellations,  as  in  HLAMatchmaker-matching  before
kidney transplantation [17]. In the first cohort, we empirically
determined  the  respective  thresholds  with  the  highest
predictive power on graft rejection for both factors. We chose
the first (“low-risk”) cohort to achieve the highest level of
statistical power during threshold estimation.
We generated two binomial factors based on the two
thresholds for tolerance and HLA-class I histocompatiblity.
These binomialized factors were then assessed in the second
cohort  for  confirmation.  The  low  versus  high-risk
classification was also fed into this confirmatory model to
control  for  potential  confounding  risk  factors  for
immunologic graft reactions.
TABLE 2. BASIC DATA OF BOTH COHORTS.
Factor Cohort 1 (n=586) Cohort 2 (n=975)
Age at time of surgery (years) 59±20 58±19
Follow up (years) 2.8±2.2 1.7±1.2
Trephine diameter (mm) 7.8±0.3 8.0±0.4
Percentage of normal risk keratoplasties 100% (586) 36% (355)
HLA-A/B Mismatches
0 3% ( 18) 4% (35)
1 11% (67) 24% (230)
2 25% (144) 28% (275)
3 40% (234) 27% (274)
4 21% (123) 17% (161)
HLA-DR Mismatches
0 11% (62) 16% (152)
1 48% (284) 51% (505)
2 41% (240) 33% (318)
           Years and millimeters are average ±standard deviation.
TABLE 3. OVERVIEW OF THE HLAMATCHMAKER-DERIVED HISTOTOCOMPATIBILITY ASSESSMENTS IN BOTH COHORTS.
Factor Cohort 1 (n=586) Cohort 2 (n=975)
Eplet mismatches HLA-A/B 20±9 17±10
Eplet mismatches HLA-DR 14±7 13±8
Tolerogenic factor (see Equation 1) −242±415 −182±408
           Maximum of eplet mismatches are 49 and 33 at HLA-A/B versus HLA-DR. The tolerogenic factor ranges from −2176 to 1025.
TABLE 4. COX PROPORTIONAL HAZARDS MODEL WITH OPTIMAL THRESHOLDS FOR THE TOLEROGENIC FACTOR AND THE
HLAMATCHMAKER EPLETS AT HLA-A/-B AS FITTED TO THE 586 NORMAL-RISK PATIENTS FROM COHORT 1.
Factor Hazards ratio p-value
Tolerogenic factor higher than 220 eplets 2.22 0.04
More than 10 HLAMatchmaker eplets at HLA-A/-B 3.63 <0.01
            Immune reactions were the only endpoint.
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2RESULTS
The first cohort: threshold determination: The thresholds with
the highest predictive power possessed 220 eplets2 for the
tolerance  factor  and  10  eplets  for  HLA-class  I
histocompatibility.  The  resulting  hazards  ratios  regarding
immune reactions were 2.22 for the tolerance factor and 3.63
for histocompatibility at HLA-class I loci A and B (Table 4).
This means that the risk of immune reactions increases 2.22-
fold in the patients with a tolerance factor >220 eplets2. The
loosely  HLA-class  I-matched  subgroup’s  risk  of  immune
reactions is 3.63 times higher than that of the more closely
matched patients. Both factors proved to be additive in a third
Cox proportional hazards model: the hazards ratio of both
binomialized factors combined to a single factor by means of
addition  was  also  highly  predictive  for  immune  reactions
(hazards ratio 2.66; p<0.01).
The  second  cohort:  confirmatory  analysis:  Both  the
binomialized tolerance factor and binomialized HLA-class I
histocompatibility  also  predicted  immune  reactions  in  the
second (confirmatory) cohort (Table 5). Again, both factors
proved to be additive in a separate Cox proportional hazards
model  (hazards  ratio  1.70;  p<0.01).  The  corresponding
Kaplan–Meier  curve  appears  in  Figure  1,  illustrating  our
findings’ clinical benefit.
TABLE 5. VALIDATION OF THE THRESHOLDS FOR HLA-CLASS I HISTOCOMPATIBILITY AND THE TOLERANCE INDUCTION FROM TABLE 4.
Factor Hazards ratio p-value
Tolerogenic factor higher than 220 eplets 2.00 <0.01
More than 10 HLAMatchmaker eplets at HLA-A/-B 1.50 0.02
Risk estimation at time of keratoplasty (low versus high risk) 0.56 <0.01
         This Cox model is fitted to cohort 2 comprising of 975 consecutive patients. The model is adjusted for low- versus high-risk
          keratoplasties. Immune reactions were the only endpoint.
Figure 1. Kaplan–Meier estimations of
rejection  free  survival  for  the  975
patients in cohort 2. The HLA-class I
matched (less or equal 10 mismatched
HLAMatchmaker  eplets)  and  non-
matched  (>10  mismatched
HLAMatchmaker  eplet  )  sub-groups
are displayed separately. More immune
reactions occur  when  tolerance factor
higher than 220 eplets   (light gray) in
comparison  to  keratoplasties  with  the
tolerance factor lower or equal than 220
eplets2  (dark  gray).  This  difference
seems to be even more pronounced in
the non-HLA-class I matched subgroup.
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2DISCUSSION
Our findings clearly indicate that matching for HLA-class I
using the HLAMatchmaker can prevent immune reactions in
normal- and high-risk keratoplasty. This finding has been
previously reported [14] and is in line with other reports on
the  conventional  HLA-matching  effect  in  keratoplasty
[18-20].
Paradoxically, matching at HLA-DR can further reduce
the risk of immune reactions when HLA-class I is only loosely
matched. We herein ascribe this unexpected finding to the
induction  of  operational  tolerance.  Our  interpretation  is
guided by the circumstance that close matches at SLA-class
II induce allo-specific tolerance in a large animal model of
kidney transplantation, despite mismatches at SLA-class I
[9]. This HLA constellation also seems to prolong kidney graft
survival in the clinical setting [8,11]. Moreover, the immune-
modulating  effect  of  HLA-DR-shared  allogeneic  blood
transfusions  on  the  allo-immune  response  after  kidney
transplantation (”pre-transfusion-effect”) has been linked to
tolerance induction [12].
We speculate that on the cellular level, donor-derived
antigen-presenting  cells  (APCs)  expose  transplantation
antigens  that  are  derived  from  mismatched  HLA-class  I
epitopes.  These  APCs  can  be  modulated  by  IL-10  to
specifically promote a regulatory immune response toward
exposed HLA-class I-derived antigens [21]. Recent findings
indicate  that  IL-10  may  in  fact  be  upregulated  in  post-
keratoplasty eyes [22]. Such modulated APCs may give rise
to  allo-specific  CD4+  regulatory  T-cells  (Tregs)  provided
donor and recipient share enough HLA-DR-derived eplets.
These Tregs may eventually permanently down-regulate the
allo-immune response toward the organ donor [23].
Interestingly,  HLA-DR  matching  is  controversial  in
keratoplasty. Concordance at the HLA-DR locus has even
been suspected of reducing graft survival in a meta analysis
[24]. However, DR-locus matching proved beneficial in a
large monocentric keratoplasty cohort [18]. This paradox was
ascribed  to  presumed  HLA-typing  errors  in  the  older
investigations [18]. An alternative interpretation may result
from the interaction with HLA-class I histocompatibility that
we are proposing. According to the equation presented above
(Methods),  unfavorable  constellations  with  respect  to
tolerance  induction  can  occur when  the  HLA-class I and
HLA-class II loci are not matched very closely.
While  HLAMatchmaker  was  designed  with  antibody
epitopes in mind, we presume that the concordance at the
HLAMatchmaker  eplet  level  also  concurs  with  T-cell
reactivity to some extent. This assumption is strengthened by
our analysis of HLA-class I histocompatibility, although it is
based  on  the  older  ('triplet')  version  of  HLAMatchmaker
[14]. We are aware of no other investigation on the newer
HLAMatchmaker class I/class II eplets in this context.
The statistical power in our investigation was reduced
because all the HLA-class I types had been performed at low
resolution. Our approach was to select the most likely four-
digit HLA-alleles based on German allele frequencies. This
approach inevitably resulted in ambiguities when assigning
the HLAMatchmaker eplets. The size of the actual effect from
our approach (Figure 1) would thus probably have been higher
based on high resolution typing.
Striving  for  utmost  coincidence  between  donor  and
recipient is associated with waiting times over a year in most
situations [6]. Herein we describe a method than can identify
a small subset of donor-recipient combinations especially at
risk  of  immune  reactions.  This  subset  is  identified  from
unfavorable donor-recipient HLA constellations with respect
to tolerogenicity, as well as HLA-class I histocompatibility.
Thinking translationally, it would be feasible to prospectively
and  systematically  avoid  these  rather  rare  graft-recipient
constellations in the clinical routine. The additional benefit
from  actively  seeking  HLA  class  I  compatible  and
tolerogeneic donors could be reserved for high-risk patients
and/or discussed with the patients individually.
In summary, our findings suggest a substantial benefit
from  the  systematic  typing  of  all  donors  and  patients,
preferably with resolution at four-digit alleles. On this basis,
long-term prognosis in keratoplasty may be improved in the
future.
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